MPMonica Puligheddu

Monica Puligheddu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Monica Puligheddu has a total of 688 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • REM atonia index cutoffs for REM sleep without atonia: a systematic review with meta-analysis of adult diagnostic performance

    by Maria P Mogavero, Giuseppe Lanza, Amedeo Antoci, Michela Figorilli, Patrizia Congiu, Federico Meloni, Monica Puligheddu, Oliviero Bruni, Carlos H Schenck, Raffaele Ferri

    Study Objectives: To synthesize evidence on REM Atonia Index (RAI) thresholds and reference values, quantify adult diagnostic performance for REM sleep behavior disorder (RBD), and distinguish diagnostic cutoffs from physiological reference limits and pediatric values. Materials and Methods: We conducted a focused systematic review of studies using automated RAI, rescreening studies from a previous review and updating PubMed/MEDLINE through July 27, 2026. Adult diagnostic accuracy was synthesized with a bivariate binomial-normal random-effects model. Continuous RAI differences were pooled as raw mean differences. Normative adult and pediatric evidence was synthesized separately because these represented different estimands. The review was retrospectively registered in OSF Registries on August 20, 2026 (https://osf.io/v3kqa). Results: Thirty unique studies were included. Eight adult studies contributed to the diagnostic-accuracy meta-analysis; thresholds ranged from 0.80 to 0.90. Pooled sensitivity was 0.850 (95% CI, 0.766 to 0.908) and specificity 0.895 (95% CI, 0.814 to 0.944). Eight studies contributed continuous data; RAI was lower in RBD by a pooled mean difference of −0.263 (95% CI, −0.335 to −0.190). Only two methodologically non-equivalent adult studies provided physiological reference limits, 0.85 and 0.91, precluding pooling. Pediatric evidence supported age-conditioned interpretation. Conclusions: Adult chin-EMG RAI shows good overall discrimination of established RBD, but current evidence does not support a universal numerical boundary for REM sleep without atonia. Evidence defining physiological reference limits is substantially less developed than diagnostic evidence, and normal RAI varies with age. RAI should therefore be reported continuously, with thresholds interpreted according to their intended diagnostic or physiological purpose.

  • Open Access

    Factors associated with post-tracheostomy survival in Amyotrophic Lateral Sclerosis

    by Alessandra Maccabeo, Sara Cabras, Stefano Callegaro, Maria Ida Pateri, Francesca Pili, Antonio Canosa, Umberto Manera, Francesca Palumbo, Enrico Matteoni, Giorgio Pellegrino, et al.

    Amyotrophic Lateral Sclerosis (ALS) is a rare neurodegenerative disease characterized by upper and lower motor neuron degeneration. It leads to progressive muscle paralysis and ultimately results i...

  • Open Access

    Beyond seizure control: Non–seizure‐related outcomes in focal‐onset epilepsy treated with adjunctive cenobamate. Third interim results from the BLESS study

    by Simona Lattanzi, Giuseppe D'ORsi, Maria Teresa Di Claudio, Alfredo D'ANiello, Stefano Luca Sensi, Fedele Dono, Mariangela Panebianco, Luigi Sicurella, Alessandra Di Liberto, Andrea Novara, et al.

    Objective: Cenobamate is approved for treatment of focal seizures in adults, but evidence on non‐seizure outcomes remains limited. This interim statistical analysis of the cenoBamate in aduLts with focal‐onsEt SeizureS (BLESS) study evaluated patient‐ and clinician‐reported outcomes for up to 52 weeks of cenobamate treatment. Methods: BLESS is an observational, retrospective and prospective cohort study designed to assess the real‐world effectiveness and safety of adjunctive cenobamate in adults with uncontrolled focal epilepsy. Outcomes included patient‐reported health‐related quality of life, sleepiness, anxiety, mood, and global functioning assessed by the 31‐item Quality of Life in Epilepsy Inventory (QOLIE‐31), the Epworth Sleepiness Scale (ESS), the Hospital Anxiety and Depression Scale (HADS), and the Clinical Global Impression (CGI) scales. Results: A total of 377 participants were included. Among subjects with an available score at 12 ( n = 197), 24 ( n = 363), and 52 ( n = 197) weeks, the QOLIE‐31 overall score remained stable. Subjects with sustained seizure freedom at 24 weeks showed a significantly higher QOLIE‐31 overall score ( p = 0.041) and cognitive functioning scores ( p = 0.019) compared with those who did not reach sustained seizure freedom. More than 68% of participants had normal daytime sleepiness (total ESS score 0–10) and did not report anxiety or depression according to the HADS‐A and HADS‐D subscales at each assessment up to 52 weeks. Clinicians rated 91.3% ( n / N = 179/196), 85.7% ( n / N = 300/350), and 87.4% ( n / N = 167/191) of subjects as improved for their overall condition from the initiation of treatment according to the CGI—Improvement or change (CGI‐I) scale, at 12, 24, and 52 weeks. Significance: This interim analysis provides preliminary descriptive evidence on non‐seizure outcomes in subjects treated with adjunctive cenobamate. Patient‐reported outcome scores remained stable from 12 weeks and up to 52 weeks, consistent with preserved overall well‐being. Better quality of life and cognitive functioning emerged in sustained vs non‐sustained seizure‐free participants. Based on clinicians' judgment, there was signal of improvement in overall condition compared to baseline in most treated subjects throughout the observation period. Study Registration: NCT05859854.

  • Open Access

    Ekbom Spectrum Psychosis Associated with 24-hour Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in Parkinson’s Disease

    by Mario Meloni, Fabrizio De Ascaniis, Gianni Orofino, Massimo Marano, Martina Mulas, Monica Puligheddu, Marcello Mario Mascia

    Mario Meloni, Fabrizio De Ascaniis, Gianni Orofino, Massimo Marano, Martina Mulas, Monica Puligheddu, Marcello Mario Mascia. Clin Psychopharmacol Neurosci 2026;24:885-9. https://doi.org/10.9758/cpn.26.1449


  • Open Access

    Restless Legs Syndrome and Mental Health Disturbances: Clinical Implications and Current Treatment Options

    by Patrizia Congiu, Martina Mulas, Maria Paola Mogavero, Giuseppe Lanza, Michela Figorilli, Monica Puligheddu, Raffaele Ferri

    Purpose of Review: Restless legs syndrome (RLS) is usually framed as a sleep-related movement disorder, but its clinical burden often depends on psychiatric symptoms, insomnia, cognitive complaints, and reduced quality of life. This review reframes recent evidence on RLS and mental health for a treatment-oriented neurology audience. Recent Findings: Recent observational and interventional studies support a bidirectional and complex relationship between RLS and depression, anxiety, and different mental health disturbances, which may worsen the RLS itself and the quality of life of patients. In this context, suicidal ideation deserves specific attention because it may persist even when depressive symptoms improve. Current treatment guidance has also shifted toward systematic evaluation of iron status, correction of exacerbating factors, and preferential use of alpha-2-delta ligands or iron therapy, with more cautious dopaminergic prescribing. Summary: RLS management should routinely include screening for mental health symptoms, sleep disruption, suicide risk, medication triggers, and comorbid sleep disorders. Conversely, patients with psychiatric disorders and sleep complaints should be screened for RLS. Integrated treatment may improve both nocturnal symptoms and daytime neuropsychiatric functioning.

  • Large muscle movements during sleep across the synucleinopathy spectrum: a polysomnographic study of isolated REM sleep behavior disorder and Parkinson’s disease

    by Maria P Mogavero, Giuseppe Lanza, Amedeo Antoci, Giovanni Pastorello, Oliviero Bruni, Bartolo Lanuzza, Monica Puligheddu, Michela Figorilli, Patrizia Congiu, Carlos H Schenck, et al.

    Study Objectives: To characterize nocturnal motor activity across isolated REM sleep behavior disorder (iRBD), Parkinson’s disease with REM sleep behavior disorder (PD+RBD), PD without RBD (PD-RBD), and healthy controls, with particular focus on large muscle group movements (LMMs) during sleep. Materials and Methods: We included 109 participants: controls (n = 25; 13F/12M, age 67.6 ± 6.70 years), iRBD (n = 25; 4F/21M, 70.7 ± 8.42 years), PD+RBD (n = 31; 10F/21M, age 71.1 ± 7.30), and PD-RBD (n = 28; 9F/19M, age 67.9 ± 8.05 years). Conventional sleep architecture, REM atonia index (RAI), leg-movement subtypes, and LMM indices and duration across total sleep time (TST), NREM sleep, and REM sleep were analyzed. Results: As expected, RAI showed the clearest group separation, with reduced values in iRBD and PD+RBD. Sleep instability, reflected by increased stage shifts, was greater in iRBD and PD+RBD than in controls. Among leg-movement measures, only isolated leg movement index remained significantly increased after correction, specifically in PD+RBD. LMM provided the most distinctive additional signal: total LMM index differed across TST, NREM, and REM sleep, with lower values in PD-RBD and higher polysomnography (PSG)–defined REM-related LMM activity in iRBD and PD+RBD. LMM duration was longer in all clinical groups than in controls, whereas LMM associated with arousal or wake did not differ significantly across groups. Conclusions: Quantitative assessment of LMM, together with refined leg-movement phenotyping and REM atonia measures, may improve characterization of nocturnal motor dysregulation across the synucleinopathy spectrum. LMM may represent a PSG-derived marker of sleep-state instability and REM-related motor activation, with potential relevance for iRBD progression and PD phenotyping. Statement of Significance This study suggests that the nocturnal motor phenotype of synucleinopathy is broader than REM sleep without atonia and conventional PLMS measures alone. By showing that LMM and isolated leg movements help distinguish iRBD, PD+RBD, and PD-RBD, the findings support a more refined polysomnographic framework for capturing disease-related motor disorganization during sleep. The contrasting profile of PD-RBD, with fewer but longer LMM, also points to nocturnal hypokinesia as a potentially distinct motor signature. If confirmed longitudinally, these measures could improve phenotypic stratification and help identify clinically meaningful pathways linked to progression, cognition, autonomic dysfunction, and future targeted treatments.

  • Repositioning Orexin in Sleep Medicine: From Wake Promotion to Sleep-State Control. A Treatment-Oriented Narrative Review

    by Maria Paola Mogavero, Giuseppe Lanza, Patrizia Congiu, Martina Mulas, Michela Figorilli, Oliviero Bruni, Monica Puligheddu, Raffaele Ferri

  • Open Access

    Protocol for the DREAMER study: design and methodological framework of a multicenter trial-ready cohort of individuals with isolated REM sleep without atonia

    by Raffaele Ferri, Monica Puligheddu, Michela Figorilli, Giuseppe Plazzi, Fabio Pizza, Luigi Ferini-Strambi, Sara Marelli, Giuseppe Lanza

    Isolated rapid eye movement sleep behavior disorder is a strong clinical marker of future alpha-synucleinopathy, but earlier stages of this risk pathway remain insufficiently characterized. Rapid eye movement sleep without atonia is the polysomnographic substrate of this disorder and may also be detected in individuals without clinical dream-enactment behavior. Whether isolated rapid eye movement sleep without atonia is a benign finding or an early risk state for future rapid eye movement sleep behavior disorder and neurodegeneration remains unknown. DREAMER is a multicenter, prospective, observational cohort protocol designed to identify adults without clinical rapid eye movement sleep behavior disorder who show isolated rapid eye movement sleep without atonia during full-night laboratory video-polysomnography. Four Italian sleep centers will use harmonized eligibility criteria, standardized clinical and sleep assessment, quantitative REM Atonia Index scoring, secure web-based data capture, and planned longitudinal follow-up. Adults aged 40 years or older undergoing video-polysomnography will be screened. Participants with prior rapid eye movement sleep behavior disorder or technically inadequate REM sleep/chin electromyographic data will be excluded. Isolated rapid eye movement sleep without atonia will be defined in participants without clinical rapid eye movement sleep behavior disorder using a REM Atonia Index threshold of <0.85. The target recruitment is more than 500 participants over 18 months, with an expected enriched subgroup of approximately 85 individuals with isolated rapid eye movement sleep without atonia. Ancillary neurophysiological assessments and blood sampling for future biomarker studies will be obtained when feasible. DREAMER is intended to create a harmonized, trial-ready cohort for evaluating isolated rapid eye movement sleep without atonia as a potential early risk marker for incident rapid eye movement sleep behavior disorder and subsequent neurodegenerative outcomes. The study is registered at ClinicalTrials.gov as DREAMER, ClinicalTrials.gov Identifier NCT06140511 .

  • Open Access

    The Italian registry for narcolepsy and central disorders of hypersomnolence (ReN&IS): Baseline clinical and diagnostic findings

    by Paola Torreri, Giorgia Buoncuore, Adele Rocchetti, Lorenzo Facciaroni, Claudio Carta, Fabio Pizza, Luca Vignatelli, Luigi Ferini Strambi, Francesco Biscarini, Massimo Zenti, et al.


  • Open Access

    Covid-19 and Shift Work: A Preliminary Note from the COVISTRESS Online Survey

    by Monica Puligheddu, Elvia Battaglia, Rosamaria Lecca, Elisa Casaglia, Michela Figorilli, Valerio Cancedda, Sara De Matteis, Maëlys Clinchamps, Reza Bagheri, Morteza Charkhabi, et al.

    Previous studies showed an increased risk of COVID-19 in several occupations, particularly healthcare workers. We aimed to explore whether night shift work, a possible determinant of immune suppression, might have contributed to COVID infection in the pre-vaccine months using data from 435 Italian participants (330 women, 105 men) to the COVISTRESS online survey. After adjusting for age, sex, and education, the risk of COVID-19 was elevated among night shift workers (OR = 5.5, 95% CI 2.92, 10.2), particularly among healthcare workers (OR = 8.7, 95% CI 4.07, 18.4). After excluding healthcare workers from the analysis, subjects working night shifts in other jobs also run a 5-fold elevated risk of COVID-19 (OR = 5.1, 95% CI 1.92, 18.4), which was confirmed in a sensitivity analysis excluding subjects who reported working remotely. Parenting school-aged children was also a significant predictor (OR = 2.5; 95% CI 1.20–5.21) of SARS-CoV-2 infection, but there was no interaction with night shift work. Education, marital status, smoking, and sleep quality did not account for the association with night shift work. Our results suggest that, during the 2020 COVID-19 pandemic, night shift workers run an excess risk of COVID-19 infection. Whether this was because of sleep loss-induced suppression of the immune system, confounding, or chance remains to be clarified.